Blood-based tumor mutational burden as a biomarker in unresectable non-small cell lung cancer treated with chemoradiotherapy and durvalumab.

In the 8.5 mut/Mb model, only PD-L1 expression ≥ 1% was significantly associated with longer PFS (HR: 0.41; 95% CI: 0.22–0.76; p = 0.002), while STK11 / KEAP1 / NFE2L2 mutations showed a trend toward shorter PFS (HR: 1.58; 95% CI: 0.78–3.24; p = 0.104; Figure 5A ).

also in 53,322 other papers

Neither bTMB nor tTMB significantly correlated with PD-L1 expression, although a weak trend toward higher bTMB was seen in patients with PD-L1 ≥ 1% (bTMB: Spearman’s ρ = 0.15, p = 0.172; tTMB: Spearman’s ρ = 0.01, p = 0.937; Supplementary Figure 1 ).

also in 1,404 other papers